Nasopharyngeal Carcinoma
Conditions
Brief summary
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
Interventions
DRUGEndostar and Envafolimab
Neoadjuvant therapy consisting of gemcitabine (1000mg/m2 d1,8) , endostar (150mg 3-day continuous infusion) and envafolimab (240mg d1) was given every 3 weeks for 3 cycles. Endostar, administered every 3 weeks (150mg 3-day continuous infusion), was given concurrently with intensity-modulated radiotherapy.
Sponsors
Zhejiang Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Aged ≥65 years with newly pathologically confirmed NPC * Karnofsky performance status ≥60 * Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition) * Adequate organ function
Exclusion criteria
* Cancer history * Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy * Life-expectance within 6 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The proportion of patients with grade 3 or higher adverse events (AEs). | Up to 24 weeks | The primary endpoint was the safety profile. AEs were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
Countries
China
Contacts
Primary ContactXiaozhong Chen
Outcome results
None listed